QL2: LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH: AN ANALYSIS OF US SURVEY DATA  by Craig, BM & Kind, P
 50
 
Abstracts
 
dures using devices to conventional open surgery. Indi-
rect cost savings benefit patients, employers and society
as a whole and therefore are important costs to consider.
METHODS: We searched the literature and identified
studies in which “indirect cost”, “convalescence” or
“work loss” were included in the analysis. All articles
published since 1990 on menorrhagia (laparoscopic hys-
terectomy/endometrial ablation versus open hysterec-
tomy), Gastroesophageal Reflux Disease (GERD) (lap-
aroscopic versus open Nissen fundoplication), and
coronary artery disease (Percutaneous Transluminal Cor-
onary Angioplasty (PTCA) versus Coronary Artery By-
pass Graft (CABG) surgery) were reviewed. Key informa-
tion abstracted included: days of work lost, direct and
indirect cost estimates, costing methodology, and follow-
up period. The percentage impact, measured as the
change in the difference between the total cost of open
surgery compared to the less-invasive procedure due to
the inclusion of indirect cost, was calculated. RESULTS:
The review produced 11 articles on menorrhagia, 5 on
GERD, and 5 on coronary artery disease. There were
large differences in the average days of work loss between
open surgery and less-invasive procedures; 21 days for
laparoscopic versus 40 days for open hysterectomy, 15
days for laparoscopic versus 35 days for open fundopli-
cation, and 27 days for PTCA versus 74 days for CABG.
The percentage impact or difference in total cost due to
the inclusion of indirect cost was on average 32.8%
(4.4%–69.4%). CONCLUSIONS: Cost savings associ-
ated with minimally invasive surgery compared to open
surgery are significantly increased when indirect costs are
included in the assessment. Future economic outcome
studies should attempt to include indirect cost measures
to fully capture the benefits of devices and minimally in-
vasive procedures.
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OBJECTIVE:
 
 The issue of whose values count in the
evaluation of health interventions is central to decision-
making in all health care systems. Within the health ser-
vices research community there is a degree of consensus
that population-based preference weights should be used
as the quality-adjustment factor in determining the value
of health outcomes. However, previous research indicates
an inverse, graded relationship between socioeconomic
status (SES) and an individual’s own health. If SES is also
found to influence the valuation of hypothetical health
states, then this could prove to have significant conse-
quences for the evaluation of treatment. METHODS:
Values for hypothetical health states defined by EQ-5D
(a generic measure of health-related quality of life) were
collected from a representative survey of the UK general
population. 2,997 individuals used time trade-off (TTO)
methods to value these EQ-5D health states. Information
on each respondent included age, gender, social class and
educational attainment. TTO values were bounded and
non-normally distributed necessitating methods such as
ordered logistic regression in addition to OLS to analyze
these data. RESULTS: Education and social class as
proxies for SES were significant predictors of the mean
values for hypothetical health states. Their influence on
health state valuation appears to act through their inter-
action with the mobility and self-care dimensions of the
EQ-5D. This relationship persists after adjustment for re-
spondent demographic characteristics. CONCLUSIONS:
Valuation of hypothetical health states appears related to
SES. This has implications for cost-effectiveness analysis
since valuations from one population with a particular
SES distribution may not be applicable for health policy
and medical decision-making in other populations. The
relationships between SES and health state valuation merit
further investigation, in particular to examine the impact
of non-health consequences such as income on values.
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OBJECTIVES:
 
 It is widely held that values of the general
public should be used in the evaluation of health care.
Surveys designed to record such values involve the partic-
ipation of individuals with different health experiences
and with different socioeconomic backgrounds. The tech-
nical performance of these participants is likely to vary as
a function of these factors, for example the logical consis-
tency of responses is often associated with socioeconomic
status. This paper examines the relationship between log-
ical consistency and respondent health using US survey
data designed to capture values for states defined by the
EQ-5D classification. METHODS: A standardised ques-
tionnaire was used to elicit valuations for EQ-5D health
states in a postal survey conducted by Johnson et al
(1998, Pharmacoeconomics) in Arizona in which US re-
spondents (N  905) rated eight states along a visual an-
alog scale from best to worst imaginable health. A logical
ordering is defined for 23 unique pairs of states in that
one state dominates the other over all 5 dimension of the
EQ-5D. A logical inconsistency was noted when a re-
spondent assigned a lower value to the “better” state in
such a pair. Censored regression models were used to as-
sess the relationship between consistency and respondent
health. We tested the robustness of these findings using
survey data from Wisconsin, which applied the same
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questionnaire (N 
 

 
 222). 
 
RESULTS:
 
 From the best imag-
inable state, each 20-point decrement in respondent’s
self-rated health status yielded significantly greater incon-
sistency in their valuation of EQ-5D health states con-
trolling for age and sex. Inclusion of education and in-
come reduced this effect slightly, yet it remained statistically
significant. CONCLUSIONS: Respondents in poor health
demonstrate greater difficult in valuing health states in a
logically consistent manner. Censoring survey data to re-
move inconsistent respondents may violate the principle
of using representative population values in evaluating
cost-effectiveness of health care.
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Increasingly over the past several years, quality of life and
patient-reported outcomes data have been submitted as
part of NDA and sNDA packages to US and Interna-
tional regulatory agencies. These data provide important
information to prescribing clinicians and patients regard-
ing therapeutic and humanistic benefits of drug therapy.
OBJECTIVES: To evaluate the marketed drugs with the
terminology ‘quality-of-life’ in the product labeling.
METHODS: A search of the Physician Desk Reference
database was conducted to identify those products that
included the term “quality-of-life” (QoL) within the Phy-
sician Package Insert. The Summary Basis of Approval
(SBA) of each product was reviewed to evaluate the re-
search processes followed, use of psychometrically vali-
dated instruments, and the final resulting language at-
tained within the labeling with respect to QoL. RESULTS:
Twenty-two products referencing the term “quality-of-
life” in the product labeling were identified. FDA ap-
proval of these products occurred mainly in the years
from 1982 to 2000 with increasing frequency of QoL in-
clusion in recent years. Upon SBA review we found the
majority of the products (13/22) utilized a validated in-
strument during clinical investigations. Only one of the
22 SBAs specifically described and discussed the issue of
instrument validation. In the early years approved label-
ing claims included more broad, sweeping terminology
when describing QoL results. In more recent, cases, ap-
proved QoL labeling claims were more narrowly defined
and more rigorously worded with respect to trial results
and specific patient-reported instruments. CONCLUSION:
Over the course of the time, the approach has become
more rigorous resulting in a more refined QoL research
process. These findings have demonstrated that the use of
QoL descriptive data has increased, particularly a greater
degree of comprehensive information pertaining to QoL
instruments, research, and data can be found in the SBAs.
Hence, more relevant and specific QoL information is
claimed in the Physician Package Insert.
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OBJECTIVES:
 
 The use of health-related quality of life
(HRQL) claims in drug promotions is under active dis-
cussion by the pharmaceutical industry, the FDA, and
other stakeholders. However, the extent to which phar-
maceutical companies have previously promoted HRQL
messages in advertisements in medical journals, and
the nature of those messages, has not been quantified.
METHODS: We performed a content analysis of all
pharmaceutical advertisements appearing in three general
medical journals (AIM, JAMA, and NEJM), and three
specialty journals (Circulation, Gastroenterology, and
Neurology) in January, July, and October annually from
1990–1999. Two reviewers analyzed each advertisement
for the presence and type of HRQL content, and for sup-
porting evidence. We distinguished explicit HRQL
claims, which used words, such as “quality of life or “pa-
tient satisfaction,” from implicit claims, which we de-
fined broadly as pictures implying improved physical,
emotional/mental, or social functioning. RESULTS: We
judged that HRQL messages appeared in 520 (24.3%) of
2142 advertisements examined. Advertisements with
HRQL content increased from 1990–94 to 1995–99
(19.9% vs. 29.6%, p  0.0001). 56% of HRQL con-
tained implicit messages only, followed by ads that used
both implicit and explicit messages (35%), and ads con-
taining explicit messages alone (9%). Overall, few ads
(12%) contained any clear supporting evidence. Mes-
sages that implied or stated improved overall well-being
or mental health were most common (78% of all HRQL
ads), followed by enhanced physical or social functioning
(63% and 25%, respectively) (numbers add to 100%,
because a single ad could contain multiple messages).
CONCLUSIONS: Advertisements conveying HRQL mes-
sages are used frequently by drug manufacturers in medi-
cal journals, and are increasing over time. In the future,
researchers should better define HRQL, and probe more
deeply into what comprises substantiating evidence, per-
haps by incorporating the concept of “patient-reported
outcomes.”
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